Allergy Therapeutics to present at EAACI 2026

AI SummaryClose X

Allergy Therapeutics plc will present data from its pollen and food allergy research at the EAACI Congress 2026, including positive safety and proof-of-concept results from the Phase I/IIa PROTECT trial of VLP Peanut and encouraging first-year safety data from the G308 Phase III trial of Grass MATA MPL in a paediatric population. The company will also host a symposium discussing new therapeutic strategies and is supporting the EAACI Early Career Research Award with a grant of up to €30,000. No new material price-sensitive information will be disclosed at the congress.

Disclaimer*

UK 100

Latest directors dealings